Chiasma secures new funding to support Phase III oral octreotide programme
This article was originally published in Scrip
Chiasma has closed $38.5 million in equity financing to fund the completion of Phase III development for Octreolin, the private company's proprietary oral form of the peptide octreotide for the treatment of acromegaly and neuroendocrine tumours.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.